Wegovy vs Ozempic: Same Drug, Different Uses

“Is Wegovy just Ozempic with a different name?” is one of the most common questions people ask when they first look into GLP-1 medications. The short version: same active ingredient, different products. The longer version matters, because the differences decide who each one is for, what dose you end up on, how it is covered, and whether a prescription is on-label or off-label.

This guide compares the two side by side using the current US prescribing information for each product, FDA announcements and NIH guidance. If you are new to the drug itself, read what is semaglutide? first, or start with the broader explainer on what a GLP-1 medication is.

The direct answer

Wegovy and Ozempic are both brand names for semaglutide, a GLP-1 receptor agonist made by Novo Nordisk. The molecule is the same. What differs is:

• The approved use. Ozempic is approved for adults with type 2 diabetes. Wegovy is approved for chronic weight management (and some related conditions) in people with obesity, or overweight plus a weight-related health problem.
• The dose range. Ozempic goes up to 2 mg once weekly. Wegovy’s usual weight-loss maintenance dose is 2.4 mg once weekly, with a higher 7.2 mg dose (Wegovy HD) for some adults, plus a once-daily tablet.
• The paperwork. Because the labels differ, prescribing Ozempic purely for weight loss is off-label, and insurance plans may treat the two very differently.

Everything else, from how they work to most side effects and safety warnings, is very similar, because it is the same drug.

Why one drug has two brand names

Drug approvals in the US are tied to specific uses, doses and products. Semaglutide was first approved in 2017 as Ozempic, a weekly injection to improve blood sugar in adults with type 2 diabetes. The company later ran a separate program of large trials testing higher doses specifically for weight loss in people with obesity or overweight, with and without diabetes. Those trials led to a separate approval under a separate name: Wegovy.

Giving the weight-management product its own brand keeps the dosing, pens and instructions distinct. It also means each label lists only the uses that were studied and approved for that product. As the Cleveland Clinic puts it, both contain semaglutide, “but their FDA-approved uses and recommended dosages differ.”

Approved uses, side by side

Here is what each US label currently lists. “Approved for” means the FDA reviewed evidence for that specific use.

	Ozempic	Wegovy
Active ingredient	Semaglutide	Semaglutide
Form	Weekly injection	Weekly injection, or once-daily tablet
Blood sugar control	Adults with type 2 diabetes (with diet and exercise)	Not an approved use
Weight reduction and long-term maintenance	Not an approved use	Adults with obesity, or overweight plus at least one weight-related condition; children 12 and older with obesity (injection)
Heart-risk reduction	Adults with type 2 diabetes and established cardiovascular disease	Adults with established cardiovascular disease and obesity or overweight (with or without diabetes)
Kidney	Lowers risk of kidney function decline, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease	Not an approved use
Liver	Not an approved use	Noncirrhotic MASH with moderate to advanced liver fibrosis in adults (injection, accelerated approval)
Maximum weekly injection dose	2 mg	2.4 mg usual maintenance; up to 7.2 mg for some adults for weight reduction

Wegovy’s heart indication was a milestone. On March 8, 2024, the FDA approved Wegovy to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight, calling it the first treatment approved for that purpose specifically in this group.

Ozempic’s heart and kidney indications, by contrast, apply to people who have type 2 diabetes. That distinction matters: the Ozempic label does not cover people without diabetes for any use.

How they work (the same way)

Because the active ingredient is identical, the mechanism is identical. Semaglutide mimics GLP-1, a hormone your gut releases after you eat. It acts on GLP-1 receptors in the pancreas, where it helps release insulin when blood sugar is high, and in the brain, where it affects appetite and fullness. It also slows how quickly the stomach empties. The net effect for most people is feeling full sooner, thinking about food less, and eating less.

The Ozempic label notes that semaglutide lowers fasting and after-meal blood sugar and reduces body weight. The difference in weight loss between the two products comes mostly from dose, and from who was studied, not from a different mode of action. For more on the biology, see how GLP-1 medications work for weight loss.

Doses: where the products really differ

Both products start low and step up slowly. This “dose escalation” is mainly there to let your digestive system adapt and reduce nausea. The schedules below are the label’s standard pattern, shown so you can understand the difference between the products. Your actual plan, including whether to move up, stay put or step back, is set by your prescriber.

Ozempic (type 2 diabetes)

• Starts at 0.25 mg once weekly for 4 weeks (a starter dose, not a treatment dose).
• Then 0.5 mg weekly.
• If more blood sugar control is needed, 1 mg, and then 2 mg, each after at least 4 weeks on the previous dose.
• Top dose: 2 mg once weekly.

Wegovy injection (weight management and other uses)

• Steps up every 4 weeks: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, then the maintenance dose.
• For weight reduction in adults, maintenance is 2.4 mg (recommended) or 1.7 mg once weekly.
• For adults who have tolerated 2.4 mg for at least 4 weeks and need more weight reduction, the label allows an increase to a maximum of 7.2 mg once weekly (sold as Wegovy HD).

Wegovy tablets

• Once daily, stepping up every 30 days: 1.5 mg, 4 mg, 9 mg, then a 25 mg maintenance dose.
• Taken in the morning on an empty stomach with up to 4 ounces of plain water, then waiting at least 30 minutes before food, drinks or other oral medicines.

Our explainer on oral semaglutide covers the tablet routine in detail.

The bottom line on dose: Wegovy’s weight-management maintenance dose (2.4 mg) is higher than Ozempic’s top dose (2 mg), and Wegovy has a further step to 7.2 mg. That is the core reason Wegovy is the product designed for weight loss.

Pens and devices are not interchangeable

The two products come in different pens and strengths. Ozempic pens are multi-dose pens that each deliver a set dose several times. Wegovy injection comes as single-dose pens, single-dose syringes, and a multi-dose FlexTouch pen that delivers four 2.4 mg doses. The current Wegovy label added a specific warning in 2026: never share a Wegovy FlexTouch pen between people, even if the needle is changed. The Ozempic label carries the same warning for its pens.

Because the strengths and devices differ, you should not try to “convert” an Ozempic dose into a Wegovy dose, or the other way round, on your own. If your treatment changes, your prescriber and pharmacist will tell you exactly which product and dose to use.

Weight loss: what the trials show

This is where people often compare numbers that were never meant to be compared. Ozempic’s trials were designed to measure blood sugar in people with type 2 diabetes; weight was a secondary result. Wegovy’s trials were designed to measure weight loss, at higher doses, alongside a reduced-calorie diet and increased physical activity.

From the current labels:

Trial (from the label)	Who	Dose	Length	Average weight change
Ozempic monotherapy trial	Adults with type 2 diabetes	0.5 mg / 1 mg weekly	30 weeks	−3.8 kg / −4.7 kg vs −1.2 kg on placebo
Wegovy Study 2	Adults with obesity, or overweight plus a condition, without diabetes	2.4 mg weekly	68 weeks	−14.9% vs −2.4% on placebo
Wegovy Study 3	Adults with type 2 diabetes and BMI 27 or higher	2.4 mg weekly	68 weeks	−9.6% vs −3.4% on placebo
Wegovy Study 8	Adults with obesity	7.2 mg vs 2.4 mg weekly	72 weeks	−18.8% (7.2 mg) vs −15.5% (2.4 mg) vs −3.9% on placebo
Wegovy Study 7	Adults with obesity, or overweight plus a condition	25 mg tablet daily	64 weeks	−13.6% vs −2.4% on placebo

A few things stand out:

1. Higher doses, longer trials, and weight as the goal produced much larger average losses in the Wegovy program. In Study 2, about 83.5% of people on Wegovy lost at least 5% of their body weight, compared with 31.1% on placebo.
2. People with type 2 diabetes tend to lose less weight on the same drug. Compare Study 2 (−14.9%) with Study 3 (−9.6%), both at 2.4 mg. The Cleveland Clinic’s endocrine pharmacist notes the same pattern and says it is likely related to other factors, since the active ingredient is the same.
3. These are averages. Individual results range widely. Some people lose much more, some much less, and some stop because of side effects.

For a broader look at the semaglutide trials, including the heart outcomes, see what is semaglutide?.

Side effects and safety: nearly identical

Since both products contain semaglutide, their safety information overlaps almost entirely.

Most common side effects (both labels): nausea, vomiting, diarrhea, abdominal pain and constipation. The Wegovy label also lists headache, fatigue, indigestion, dizziness, bloating, belching, gas, reflux and hair loss among its common reactions. Digestive side effects tend to show up when you start or increase the dose, which is why the slow step-up exists. Practical help is in our guides to GLP-1 nausea and constipation and diarrhea on GLP-1s.

Same boxed warning. Both carry a boxed warning that semaglutide caused thyroid C-cell tumors in rodents; it is unknown whether it causes them in humans. Both are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2), and in people with a serious allergy to semaglutide.

Shared warnings and precautions include:

• Acute pancreatitis (stop and seek care if it is suspected).
• Gallbladder problems such as gallstones.
• Low blood sugar, especially when combined with insulin or a sulfonylurea.
• Acute kidney injury from dehydration after vomiting or diarrhea.
• Severe digestive reactions; neither is recommended for people with severe gastroparesis.
• Serious allergic reactions.
• Worsening diabetic eye disease in people who already have diabetic retinopathy.
• Risk of breathing food into the lungs during anesthesia or deep sedation, so tell your care team about any planned procedure.

The Wegovy label also notes a small increase in resting heart rate (on average 1 to 4 beats per minute in weight-reduction trials) and advises regular monitoring.

Dose matters. Higher doses can mean more side effects. As the Cleveland Clinic’s pharmacist explains, you are likely to experience more side effects at higher doses of semaglutide, which is one reason people often move up more slowly or stay at a lower step when they struggle.

Pregnancy. Both labels advise stopping at least 2 months before a planned pregnancy, because semaglutide takes weeks to leave the body. NIH guidance says weight-management medicines should not be used during pregnancy.

Never take them together. The Wegovy label says it should not be used with other semaglutide-containing products or with any other GLP-1 receptor agonist. Doubling up raises the risk of side effects without a proven benefit.

On-label vs off-label: why it matters for you

A clinician can legally prescribe an approved medicine for a use that is not on its label. That is called off-label prescribing, and it is common across medicine. NIDDK, part of the NIH, explains that off-label use for weight can mean a drug approved for a different medical problem, and adds: “You should feel comfortable asking whether your health care professional is prescribing a medication that is not approved for treating overweight and obesity.”

For Ozempic, weight loss alone is off-label. In practical terms:

• The evidence base is different. Wegovy’s dosing and safety for weight management were tested in people without diabetes. Ozempic’s label was built on studies in people with type 2 diabetes.
• The dose ceiling is lower. Ozempic stops at 2 mg; the Wegovy weight-management dose is 2.4 mg or higher.
• Coverage can differ. Insurers decide coverage by plan, and many tie it to an approved diagnosis. A plan that covers Ozempic for type 2 diabetes may not cover it for weight loss, and coverage for weight-management drugs like Wegovy varies.

If you have type 2 diabetes and overweight or obesity, either product may be on the table, and the choice depends on your goals, other conditions, other medicines and coverage. If you do not have diabetes, Wegovy is the semaglutide product approved for weight management. Our guide to who qualifies for GLP-1 weight-loss treatment explains the BMI and health criteria.

Cost and insurance

List prices, savings programs and cash-pay options change often, so we keep the numbers in one place: see semaglutide cost without insurance and the GLP-1 costs hub.

A few principles hold steady:

• NIDDK notes that some, but not all, insurance plans cover medicines that treat overweight and obesity. Call your plan and ask about the specific product, its formulary tier, and whether prior authorization is required.
• Coverage of Ozempic usually depends on a type 2 diabetes diagnosis.
• Paying cash for one product does not change its approved use or safety rules.

Shortages, compounded versions and fakes

During the shortage years, many people were offered compounded semaglutide. On February 21, 2025, the FDA determined that the semaglutide injection shortage, which began in 2022, was resolved. The agency gave compounders a transition period: until April 22, 2025, for state-licensed pharmacies and physicians, and until May 22, 2025, for outsourcing facilities, to stop making copies of the approved products that had been allowed because of the shortage.

Two points from FDA are worth knowing:

• Compounded drugs are not FDA-approved. FDA says unapproved versions of GLP-1 drugs, including semaglutide, do not go through its review for safety, effectiveness and quality before they are marketed.
• Counterfeits exist. FDA has warned about counterfeit Ozempic in the US, which may contain the wrong ingredient, the wrong amount, or none at all. FDA advises getting prescription medicines only with a valid prescription from a state-licensed pharmacy.

Compounded products are neither “generic Wegovy” nor “generic Ozempic.” We cover the differences in the semaglutide hub, and our guide to how telehealth weight-loss programs work lists FDA’s red flags for online sellers.

Common myths, corrected

“Ozempic and Wegovy are exactly the same, so it doesn’t matter which one you get.” The molecule is the same, but the doses, devices, approved uses and coverage are not. Those differences are real and practical.

“Ozempic only goes up to 1 mg.” The current Ozempic label lists 2 mg once weekly as the top dose for blood sugar control. Older information online may be out of date.

“You can combine two pens to reach a higher dose and save money.” Do not improvise doses or combine pens. Each pen is designed for specific doses, and dosing outside the label without your prescriber’s direction raises the risk of side effects and errors.

“Wegovy is stronger, so it is more dangerous.” It is the same drug at a higher dose. Digestive side effects can be more common at higher doses, but the warnings are essentially the same. Dose escalation exists to make the higher dose tolerable.

“Ozempic is a diabetes drug, so it can’t help the heart.” Ozempic is approved to reduce major cardiovascular events in adults with type 2 diabetes and established heart disease, and Wegovy is approved for a similar purpose in adults with overweight or obesity and heart disease.

How to decide, with your clinician

This is a decision for you and a licensed clinician who knows your history. These questions can make the conversation more productive:

1. Do I have type 2 diabetes, prediabetes, heart disease, kidney disease or fatty liver disease, and does that change which product fits?
2. Is the product you are suggesting being used on-label or off-label for me?
3. Weekly injection or daily tablet? What does each routine involve?
4. What dose will we aim for, and how will we handle nausea or other side effects during the step-up?
5. Do any of my current medicines (especially insulin, sulfonylureas, or oral medicines that need careful timing) need adjusting?
6. What will my plan cover, and is prior authorization needed?
7. How will we protect muscle while I lose weight? (See how much protein you need on a GLP-1 and strength training on GLP-1s.)
8. What is the long-term plan if the medicine works, or if it does not?

If you are still at the stage of figuring out how to get evaluated, our step-by-step guide on how to get a GLP-1 prescription walks through the visit, labs and pharmacy.

Where tirzepatide fits

People comparing Wegovy and Ozempic often hear about Zepbound and Mounjaro too. Those brands contain a different drug, tirzepatide, which activates both GIP and GLP-1 receptors, and the same “one drug, two brands” logic applies: Mounjaro for type 2 diabetes, Zepbound for weight management. Our Zepbound vs Mounjaro guide compares that pair. Learn more in what is tirzepatide? and our semaglutide vs tirzepatide guide. For the full list of medicines with a weight-management approval, see which GLP-1s are FDA-approved for weight loss.

The bottom line

Wegovy and Ozempic are the same medicine, semaglutide, packaged and approved for different jobs. Ozempic is a type 2 diabetes treatment that also lowers heart and kidney risk in some people with diabetes, with a top dose of 2 mg weekly. Wegovy is the semaglutide product approved for weight management, heart-risk reduction in people with overweight or obesity and heart disease, and a form of fatty liver disease, with a usual maintenance dose of 2.4 mg weekly, a 7.2 mg option for some adults, and a daily tablet. Their side effects and safety warnings are nearly identical. The right choice depends on your diagnosis, goals, other medicines and coverage, and it should be made with a clinician, not by swapping pens or doses on your own.

Explore more in the semaglutide hub and the GLP-1 Guide hub.